Project description
Frame-shift mutation based anticancer vaccination
Immunotherapy shows impressive potential for cancer treatment. This approach involving the general activation of the immune system would benefit dramatically if combined with tumour-specific vaccination. This is now possible with technology enabling routine sequencing of the entire tumour DNA within two weeks. Frame Cancer Therapeutics has developed a new kind of personalised anticancer vaccine based on shared neoantigens induced by frameshift mutations. These sequences are not normally expressed, and are thus attacked by the immune system, enabling specific vaccines for different tumour types. The EU-funded project focuses on the development of specific sets of vaccines for cancers according to their shift-mutations, providing an effective and less-expensive approach compared to point-mutation based neoantigen vaccination.
Fields of science
- social scienceseconomics and businessbusiness and managemententrepreneurship
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesgeneticsmutation
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1
Coordinator
1098 XG Amsterdam
Netherlands
See on map